What is the Semax and Selank stack?

The Semax and Selank stack pairs two Russian neuropeptides with complementary cognitive and anxiolytic mechanisms. Semax is an ACTH-derived heptapeptide that boosts BDNF and NGF, enhances dopaminergic and serotonergic signalling, and improves cognitive performance and neuroprotection. Selank is a tuftsin analogue that modulates GABAergic and serotonergic pathways, producing anxiolytic effects without sedation. Together, they are reported to support both cognitive performance and emotional regulation.

Do Semax and Selank work well together?

Semax and Selank are frequently described in nootropic research communities as complementary. Semax drives cognitive performance and neuroplasticity through BDNF/NGF upregulation and dopaminergic stimulation. Selank reduces anxiety and stress via GABAergic modulation, creating a calmer mental state in which the cognitive effects of Semax may be more fully expressed. Both peptides upregulate BDNF, which may produce additive neuroplasticity effects. Selank's anxiolytic action may also blunt the mild stimulatory edge that some researchers report with Semax alone.

What is the protocol for the Semax Selank stack?

Both compounds are most commonly reported as intranasal administration. Semax is typically used at 200 to 600 mcg per day, applied as 1 to 2 drops per nostril, cycling 2 weeks on and 2 weeks off. Selank is typically used at 250 to 500 mcg per day with a similar cycling approach. Both are often taken together in the morning. Some researchers use Selank on high-stress days and Semax on cognitively demanding days, rather than always together.

Is Semax or Selank better for anxiety?

Selank is considered the more targeted anxiolytic of the two. Its mechanism involves GABAergic modulation and enkephalin protection, producing calming effects without the sedation associated with classical anxiolytics. Semax can have a mildly stimulating effect that some researchers find counterproductive for acute anxiety. For anxiety-focused research, Selank is typically the primary compound, with Semax added for concurrent cognitive support if desired.

Can Semax and Selank be taken at the same time?

Anecdotal research accounts commonly describe taking Semax and Selank intranasally at the same time of day, typically in the morning. No pharmacological interaction between the two has been identified in research or anecdotal reports. No combination-specific safety concerns have been raised. Both compounds are short-acting and are typically cleared within a few hours of intranasal administration.

Semax + Selank, Cognitive and Anxiety Stack Research Reference

The Semax + Selank combination is the most widely discussed cognitive and anxiolytic peptide stack in nootropic research communities. Both compounds are Russian neuropeptides with clinical research backing in their country of origin, and both share the intranasal route of administration. Their mechanisms are complementary: Semax drives cognitive performance and neuroplasticity; Selank modulates anxiety and stress response.

Stack Overview

Parameter	Detail
Components	Semax + Selank
Mechanisms	BDNF/NGF upregulation, dopaminergic stimulation (Semax) + GABAergic modulation, anxiolytic, enkephalin protection (Selank)
Primary reported goal	Cognitive enhancement, anxiety reduction, neuroprotection
Category	Cognitive / Anxiety

Research context: Both compounds have Russian clinical research backing, including use in approved indications in Russia (Semax for stroke recovery, neurological conditions; Selank for anxiety disorders). Large-scale Western RCT data is limited. The combination is primarily researched anecdotally. Neither compound is FDA-approved.

Components

Component	Class	Primary Mechanism	Standard Research Form
Semax	ACTH(4-7) heptapeptide	BDNF/NGF upregulation, dopamine/serotonin modulation, neuroprotection	Intranasal 200 to 600 mcg per day
Selank	Tuftsin analogue heptapeptide	GABAergic modulation, anxiolytic, serotonin regulation, BDNF upregulation, enkephalin protection	Intranasal 250 to 500 mcg per day

For individual compound profiles, see:

Commonly Reported Protocol

The following information represents commonly reported research ranges from anecdotal accounts. These are not medical recommendations.

Standard Intranasal Protocol

Both compounds are administered intranasally in the majority of research accounts. Intranasal delivery allows direct transport along the olfactory pathway to the central nervous system, bypassing the blood-brain barrier:

Parameter	Commonly Reported Range
Semax dose	200 to 600 mcg per day
Selank dose	250 to 500 mcg per day
Administration	1 to 2 drops per nostril per compound
Timing	Morning, typically taken together
Cycle	2 weeks on, 2 weeks off (commonly described)

Alternative Approaches

Some researchers in anecdotal accounts describe two alternative approaches rather than fixed daily co-administration:

Needs-based approach: Selank on high-stress or anxiety-predominant days. Semax on cognitively demanding days. Compounds are used selectively based on the immediate need rather than always together.

Sequential dosing: Selank taken first (30 minutes before Semax) to establish a calm baseline before adding the more stimulatory cognitive effects of Semax. This approach is sometimes described for researchers who find Semax slightly activating.

Reported Synergies

The Semax and Selank combination is proposed to work through distinct but mutually supporting mechanisms:

Cognitive performance and calm baseline: Semax’s cognitive enhancement and neuroplasticity effects may be more fully expressed when the underlying state of stress and anxiety is modulated by Selank. Selank’s anxiolytic action without sedation provides a calmer mental state that may allow clearer expression of Semax’s cognitive benefits, rather than the cognitive impairment that high anxiety or stress typically produces.

Dual BDNF upregulation: Both Semax and Selank have been reported to upregulate brain-derived neurotrophic factor (BDNF), a key protein in neuroplasticity, memory formation, and neuroprotection. The additive or synergistic BDNF effect from two distinct upstream pathways may enhance neuroplasticity effects beyond either compound alone.

Complementary neurotransmitter profiles: Semax modulates dopaminergic and serotonergic systems primarily in the direction of cognitive activation. Selank modulates GABAergic and serotonergic systems primarily in the direction of anxiolysis. These complementary effects on overlapping neurotransmitter systems may produce a balanced cognitive and emotional state rather than the imbalanced stimulation or sedation that single-compound approaches sometimes produce.

No known antagonism: No pharmacological antagonism between Semax and Selank has been identified in published research or anecdotal reports.

Reported Effects

The following effects have been reported in anecdotal research accounts and, to varying extents, in published research on the individual compounds.

Cognitive Enhancement

Semax is the primary cognitive driver in this stack. Anecdotal research accounts describe improved focus, working memory, processing speed, and motivation. Published Russian research has documented cognitive-protective and neurorestorative effects in stroke recovery and other neurological contexts. BDNF upregulation is considered a central mechanism.

Anxiety Reduction Without Sedation

Selank’s most consistently reported effect is anxiolytic action without the sedation associated with classical anxiolytics (benzodiazepines, buspirone). Anecdotal research accounts describe reduced anxiety, improved stress response, and emotional stability without cognitive impairment or fatigue. Russian clinical research has documented anxiolytic effects in clinical populations.

Neuroprotection

Both compounds have been associated with neuroprotective effects in animal research. Semax has demonstrated protection against ischaemic damage in animal models. Selank’s enkephalin protection mechanism is proposed to reduce neuronal stress response and support neuronal survival. Anecdotal research accounts sometimes describe subjective improvements in mental resilience.

Sleep and Recovery

Some researchers describe improved sleep quality with Selank use, particularly reduction in stress-related sleep disturbance. Semax is not typically described as sleep-promoting and some researchers note it is better used in the morning rather than before sleep.

Reported Side Effects

Side Effect	Frequency Reported
Nasal irritation or mild burning (intranasal)	Common with any intranasal peptide
Mild headache	Occasionally reported with Semax
Initial mild stimulation or restlessness (Semax)	Occasionally reported, typically subsides
Mild fatigue following Semax use	Occasionally reported
Transient mood changes	Rarely reported

Regulatory note: The FDA has flagged compounded Semax preparations for potential safety concerns including immunogenicity risk and aggregation issues with improperly prepared formulations. These concerns relate to compounding quality rather than the compound itself. Researchers should obtain Semax from sources with documented quality controls.

Neither compound is approved for human use in the United States, United Kingdom, or most Western jurisdictions. Both are used as research compounds.

Research Context

Semax and Selank were both developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and have regulatory approval in Russia for specific clinical indications. Semax is approved in Russia for treatment of cerebral ischaemia and other neurological conditions. Selank is approved in Russia for the treatment of generalised anxiety disorder.

In Western research communities, both compounds are used as unregulated research compounds. The combination is primarily researched anecdotally with a large body of self-reported data from nootropic research communities. No published clinical trial has studied the combination specifically.

Frequently Asked Questions

Can Semax and Selank be stacked with other nootropics? Anecdotal research accounts describe both compounds alongside racetams, adaptogens, and other neuropeptides. Common additions described include Cerebrolysin (for additional neurotrophic support) and Dihexa (for BDNF signalling). No known interactions have been identified with standard nootropic compounds, though formal combination data is absent. See Cerebrolysin Research Reference and Dihexa Research Reference.

How long before effects are reported with this stack? Anecdotal accounts most frequently describe noticing anxiolytic effects from Selank within 30 to 60 minutes of intranasal administration, with cognitive effects from Semax described as beginning within 20 to 40 minutes. Cumulative neuroplasticity effects from BDNF upregulation are proposed to build over days to weeks of consistent use.

Is intranasal the only route for this stack? Intranasal is the predominant route described for both Semax and Selank in research communities. Subcutaneous injection has been described for Semax in some accounts and may produce different pharmacokinetic profiles. Intranasal is considered the practical and commonly reported approach due to ease of administration and proposed CNS access.

What does the Semax vs Selank comparison page cover? The Semax vs Selank comparison provides a structured side-by-side overview of mechanisms, half-lives, dosing, and reported use cases for the two compounds as alternatives, complementing this page’s focus on their use together.

Should Semax be taken in the morning? Anecdotal research accounts predominantly describe Semax as a morning compound due to its mild activating effects on dopaminergic and serotonergic systems. Taking Semax close to sleep onset may interfere with sleep quality in some researchers’ accounts. Selank is more neutral in terms of timing but is also typically described as a morning or daytime compound.

CJC-1295 + Ipamorelin, GH axis optimisation for recovery and body composition
GHK-Cu + Epitalon, Longevity-focused anti-ageing stack
Semax vs Selank Comparison
Semax vs Cerebrolysin Comparison